2007: Spondylarthropathies and Psoriatic Arthritis: Treatment I
Search or Browse by Day

Spondylarthropathies and Psoriatic Arthritis: Treatment I

578
Adalimumab Reduces the Incidence of Uveitis Flares in Patients with Ankylosing Spondylitis (AS)
579
Correlation of Biomarkers with Clinical Parameters in AS Patients without and during Treatment with TNFalpha Blocking Reagents
580
Changes in Markers of Bone Metabolism and Bone Mineral Density in Patients with Active Ankylosing Spondylitis During Treatment with Tnf-Blockade
581
2-Year Safety and Efficacy Results From the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (ATLAS)
582
Prediction of Persistent Partial Remission in Active Ankylosing Spondylitis Treated with Infliximab over 3 Years
583
Analysis of Risk Factors for Radiographic Progression in Psoriatic Arthritis (PsA): Subanalysis of ADEPT
584
Psoriasis Patients with or without Psoriatic Arthritis Experience Improvements in Skin and in Patient-Reported Outcomes upon Treatment with Adalimumab: Results from the First 16 Weeks of REVEAL
585
To what Degree do the BASDAI and BASFI Questionnaires Address the Most Essential Symptoms and Disabilities of Patients with Ankylosing Spondylitis?
586
Perceived Locus of Control and Coping as Major Factors Influencing Attainment of the Patient Acceptable Symptom State (PASS) in Ankylosing Spondylitis
587
Development of Diagnostic Criteria for Inflammatory Back Pain in Ankylosing Spondylitis Based on a Simple 2-Item Questionnaire
588
Diagnostic Criteria for Inflammatory Back Pain in Ankylosing Spondylitis: Does Sex, Symptom Duration, and Pain Level Influence the Diagnostic Value of Criteria Based on the History?
589
Scoring of Radiographic Progression Over 2 Years with the mSASSS in Ankylosing Spondylitis: Does Training Improve Reliability?
590
Changes in Plasma IL-6, VEGF, YKL-40 and COMP in Spondyloarthritis Patients During Treatment with TNFα Inhibitors
591
Rates of IBD in Patients Receiving Etanercept and Placebo in AS
592
Evaluation of the Efficacy and Safety of Repeated Intra-Articular Etanercept Injections in Resistant Knee Joint Synovitis
593
Onset of Psoriatic Arthritis in Patients Treated with Efalizumab for Severe Cutaneous Psoriasis
594
Adalimumab Improves Peripheral Arthritis and Enthesitis in Addition to Axial Signs and Symptoms in Patients with Ankylosing Spondylitis (AS): The RHAPSODY Trial
595
Prevalence of Enthesitis and Utility of Two Enthesitis Index in Ankylosing Spondylitis and Psoriatic Arthritis
596
Factors Associated to Employment in Ankylosing Spondylitis and Psoriatic Arthritis
597
Clinical and Radiographic Differences between Primary Ankylosing Spondylitis, Psoriatic Spondylitis and Spondylitis Associated with Inflammatory Bowel Disease
598
Sacroiliac Joint Osteoarthritis in Females is a Distinct Clinical Entity Unrelated to Spinal Osteoarthritis
599
Ankylosing Spondylitis (AS) is a Progressive Disease Without Burn-Out in the Majority of Patients
600
Enthesis Inflammation in Recurrent Acute Anterior Uveitis without Spondyloarthropathie
601
Strict Adherence to BASDAI Scores May Mislead the Treatment Decisions in Patients with Ankylosing Spondylitis
602
TNF Alpha Gene Promoter Polymorphisms at Position -308 and Ankylosing Spondylitis Severity
603
A Pilot Study with Referred Patients Suffering Early Spondyloarthropathies: Results of ESPIDEP Study
604
Erythrocyte Sedimentation Rate Predict Progression of Enthesis Lesion in Spondyloarthropathies
605
Comparison of 4 Functional indexes in Psoriatic Arthritis Using Rasch Analyses
606
The Psoriatic Arthritis Cost Evaluation (PACE) Study: A Cost-of-Illness Study on Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients with Inadequate Response to Conventional Therapy
607
Determinants of Willingness to Pay for 8 Qol Domains in Psoriatic Arthritis Patients
608
The PASE Questionnaire: Pilot-Testing a Psoriatic Arthritis Screening and Evaluation Tool
609
Cardiovascular Risk Factors in Patients with Psoriatic Arthritis Compared to Healthy Controls
610
Patient and Physician Perception of Disease in Psoriatic Arthritis (PsA). A Multicentre GRAPPA and OMERACT Study
611
10 Year Cardiovascular Risk in Patients with Psoriatic Arthritis
612
Association of Radiographic Damage with Functional Limitations in Ankylosing Spondylitis: Differences between Patients with Early and Long-Standing Disease
613
Ultrasonography In The Berlin’S Algorithm For The Diagnosis Of Early Spondyloarthropathy.
614
Clinical Tests for Sacroiliitis and Spinal Mobility - no Helpful Tools for Diagnosing Axial Spondyloarthritis (SpA) Early
615
Do We Really Need to Evaluate Entire Cervical Spines for Squaring Score in Modified Stoke Ankylosing Spondylitis Spinal Score?
616
Worker Productivity in Ankylosing Spondylitis: Absenteeism and Presenteeism
749
Efficacy, Safety, and Tolerability of Infliximab in Juvenile-onset Spondyloarthropathies (JO-SpA): Results of the Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial Phase
750
Examination of the Association of Clinical Descriptors with Radiographic Findings in a Primary Back Pain Cohort
751
Radiographic Progression in Ankylosing Spondylitis (AS) - The Natural Course. A Retrospective Cohort Study
752
Sustained Disease Activity in Ankylosing Spondylitis: A Prospective Study
753
Efficacy of Adalimumab in the Treatment of Preradiographic Axial Spondyloarthritis: 52-Week Results of a Randomized Controlled Trial and Open-Label Extension
754
Drug Discontinuation Due to Inefficacy in Ankylosing Spondylitis Patients Treated with Anti-TNF drugs: Results from the British Society for Rheumatology Biologics Register (BSRBR)
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>